Planul Național De Combatere A Cancerului

Objectives

The National Plan for Cancer Prevention and Control in Romania is the principal public-policy framework for 2023–2030, aiming to reduce cancer morbidity and premature mortality through prevention, early detection, diagnosis, treatment, survivorship support and palliative care.[1][2][3]It guarantees eligible citizens and residents access to medical, social and psychological support, including prevention, diagnosis, treatment, psycho-oncology, onconutrition, oncofertility, palliative care and social assistance.[1][4]The Plan is to be updated according to achieved results and relevant World Health Organization and European Union strategic directions.[1][2]

• Strengthen primary prevention by addressing tobacco, alcohol, ultraviolet radiation, pollution, benzene, radon, nutrition, stress and other modifiable cancer risks.[5][6][7]
• Establish population-based screening and earlier-diagnosis pathways for colorectal, breast, cervical, bronchopulmonary, prostate, haematological and rare cancers, with particular emphasis on reducing late-stage diagnosis.[8][9][10][11][12][13][14]
• Improve integrated, multidisciplinary and personalised care through standardised patient pathways, tumour boards, biomarker and genomic testing, interoperable health data, registries and cancer-centre networks.[15][16][17][18][19]
• Expand disease-specific capacity, including accredited centres for complex colorectal, breast, cervical, bronchopulmonary and prostate cancer treatment, regional acute-leukaemia centres, rare-cancer centres of expertise, and paediatric oncology services.[20][21][22][23][24][25][26]
• Improve quality of life through palliative, psychological, nutritional, fertility-related, rehabilitation and long-term survivor support, including dedicated services for children, adolescents and young adults.[27][28][29][30][31]
• Advance research and innovation through personalised medicine, genomic and multi-omics capacity, clinical trials, a Cancer Mission Competence Centre, living laboratories and participation in European research partnerships.[32][33][34][35]

Implementation

Implementation combines national stewardship by the Ministry of Health with shared delivery and financing responsibilities for the National Health Insurance House and Ministry of Finance.[36][4]Central and local public authorities, legally organised providers, professional bodies, universities, patient organisations, research institutions, private partners and other individuals and legal entities are expected to contribute to fulfilling the Plan’s measures.[2][4][37]Delivery is intended to be multidisciplinary, regionally coordinated and linked to European Union programmes, including the National Recovery and Resilience Plan, the Health Programme 2021–2027 and the European Beating Cancer Plan.[38][39][33]

• Coordinate planning, initiation, monitoring and evaluation through the Ministry of Health, while assigning operational and financing roles to the National Health Insurance House and Ministry of Finance where measures require new services, infrastructure or substantial investment.[36][40][41]
• Deliver integrated patient pathways by setting time standards from suspicion to diagnosis and treatment, strengthening family-doctor referral, patient navigation, priority waiting lists, diagnostic capacity and data interoperability.[16][42]
• Develop screening through organised population programmes, pilot projects, regional networks, family-doctor engagement, quality assurance, registries and follow-up systems.[43][44][45][10]
• Implement personalised medicine by financing biomarker, immunohistochemical, genetic and comprehensive genomic testing through National Oncology Programme sub-programmes, with potential contributions from marketing-authorisation holders for relevant personalised medicines.[46][17][47]
• Build information infrastructure by establishing a functional National Cancer Registry and disease-specific sub-registers, enforcing mandatory reporting, operationalising the Electronic Health Record and aligning data systems with the European Health Data Space.[48][49]
• Apply quality assurance through multidisciplinary tumour boards, accreditation standards for cancer and radiotherapy centres, treatment protocols, clinical guidelines, staff training and annual review of tumour-board activity.[18][28][20]
• Mobilise resources through state-budget financing, including a minimum annual allocation of at least 20% of funds approved for national health programmes, with unspent Plan allocations carried forward and protected from negative budget revisions.[4]The Plan also proposes targeted reimbursement and supplementary per-patient financing for selected high-cost services and accredited centres.[20][22][23][24]
• Monitor progress using mortality, incidence, stage at diagnosis, screening participation, service-network coverage, treatment performance, registry completeness, prevention expenditure and patient-pathway indicators.[50][51][7][8][12]Several extracts do not specify a complete reporting schedule, unified evaluation methodology or formal accountability framework beyond named responsible institutions and selected targets.[36][14][52]

Monitoring & Evaluation

Monitoring combines national oversight by the Ministry of Health with disease-specific targets, pathway standards, registries and service-quality measures, but the supplied material does not establish a single comprehensive reporting, evaluation or accountability framework for the National Plan.[36][2][49]

• Monitor implementation and evaluate cancer-control measures through the Ministry of Health, while the National Health Insurance House supports operationalisation, monitoring and uniform application.[36][40]
• Update the Plan according to achieved results and strategic directions of the World Health Organization and European Union.[1][2]
• Track cancer incidence by site, diagnosed cases and mortality by cancer type, alongside prevention expenditure and risk-factor activity measures.[50][7]
• Establish the National Cancer Registry with mandatory core variables, centre-level results and legally enforceable reporting; possible non-compliance consequences include suspension of funding and management-performance criteria.[48][49]
• Use explicit outcome targets, including a 5% mortality-reduction objective in amended objectives, 15% mortality reductions for breast and cervical cancer, annual 3.5% mortality reduction for bronchopulmonary and rare cancers, and annual 10% mortality reduction for prostate cancer.[53][54][55][11][56][14]
• Monitor screening and pathway performance through target populations, stage at diagnosis, pathway time indicators, screening-quality data and therapeutic-performance indicators.[8][57][10][55][58]
• Measure diagnostic-pathway performance against a 30-day diagnosis target and a 60-day maximum from suspicion to treatment initiation.[16]
• Assess tumour-board activity and implementation of decisions annually.[18]
• Strengthen surveillance through cancer registries, including the National Childhood Cancer Registry and disease-specific haematological registries, while addressing major gaps in rare and haematological cancer data.[59][60][61][62]
• Publish clinical-study sites and recruitment status, and apply a 30-day target for resolving clinical-study applications.[35]
• Recognise that many sections do not specify indicator definitions, reporting cycles, independent evaluation methods, surveillance platforms or formal sanctions beyond the registry-reporting provisions.[36][49][52]

Costing & Financing

Financing is principally state-budget based, with a minimum annual allocation for the Plan and supplementary reimbursement, programme, European funding and private-sector contribution mechanisms. However, most measures lack quantified budgets, costing methodologies, funding-gap estimates or wider economic assumptions.[4][17][34][52]

• Finance the Plan primarily through the Ministry of Health from the state budget, with an annual allocation of at least 20% of total Ministry of Health and National Health Insurance House funding approved for national health programmes; carry forward unspent funds and protect allocations from negative budget revisions.[4]
• Allocate state-budget funding for reimbursement of Plan-related services and investigations separately from social health insurance and other national curative or preventive programmes.[63]
• Require budget-impact analysis and substantial allocations for new infrastructure, high-cost services, workforce training, digital systems and research capacity.[64][65][66]
• Coordinate investment with the National Recovery and Resilience Plan, the Health Operational Programme 2021–2027 and relevant European Union programmes.[67][68][33][34]
• Fund genetic, immunohistochemical and comprehensive genomic testing through sub-programmes within the National Oncology Programme, potentially supplemented by pharmaceutical marketing-authorisation holders where health-insurance resources are limited.[17][47][69]
• Establish a four-year Health Innovation Fund budget to support earlier reimbursement of innovative medicines, using discounted prices negotiated with manufacturers.[70]
• Provide specified supplementary per-patient payments for accredited colorectal, cervical, bronchopulmonary and prostate cancer services and minimally invasive surgery.[20][22][23][24]
• Use non-governmental funding for the National Childhood Cancer Registry and identify European funding for research, paediatric services and acute-leukaemia regional centres.[25][62]
• Note contextual economic evidence: European Union cancer-treatment expenditure increased from 52 to 103 billion euros between 1995 and 2018, while cancer-medicine expenditure rose from 14.6 to 32 billion euros between 2008 and 2018.[70][71]
• Recognise that colorectal cancer has an estimated total cost of 19 billion euros and that sustainable financing for a nationally regulated screening programme has not been specified.[72][43]